Xenon Pharmaceuticals provided an update on its pipeline programs, highlighting significant progress and upcoming milestones for 2025. The company anticipates topline data from its first Phase 3 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback